Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
proagio
- Development stage
- Phase 2
- Lead developer
- ProDa BioTech
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
ProAgio is a pegylated peptide drug developed from a human protein that targets and kills cells expressing integrin αvβ3, such as cancer-associated fibroblasts (CAFs) and endothelial cells. By binding to the αvβ3 integrin receptor, which is present on abnormal endothelial cells forming tumor blood vessels and on CAFs that generate the physical barrier around tumors, ProAgio induces apoptosis in these cancer-supporting cells. This mechanism disrupts the dense stroma of solid tumors—such as pancreatic cancer and triple-negative breast cancer—improving drug delivery to tumor sites by reopening collapsed blood vessels and reducing irregular angiogenic vasculature. Preclinical studies have shown efficacy in murine models of pancreatic and breast cancers, with ongoing clinical trials evaluating its safety and recommended dosing in humans[1][4][5][6][7].
- Brand names
- ProAgio
- Other names
- ACT-50ACT50ACT 50
02
Targets
αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on proagio.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on proagio.